Wilmer Cutler Pickering Hale and Dorr has advised Spero Therapeutics. Sidley Austin LLP has advised HealthCare Royalty. Spero Therapeutics, Inc. (NASDAQ: SPRO), a clinical-stage biopharmaceutical company,...
Spero Therapeutics Secures $105 Million Royalty Financing and Exclusive License for SP001
Apnimed Secures $150 Million Debt Financing and Monetizes SASS Joint Venture Stake
Hogan Lovells has advised HealthCare Royalty Partners. Goodwin has advised Apnimed, Inc. Apnimed, Inc., a pharmaceutical company focused on developing oral therapies for obstructive sleep apnea...
HealthCare Royalty Monetizes Royalties on Modeyso Sales
Sidley has advised HealthCare Royalty on the transaction. HealthCare Royalty has entered into a royalty monetization agreement with the Advisory Group representing the former Oncoceutics, Inc....
KKR Acquires Majority Stake in HealthCare Royalty Partners
Debevoise & Plimpton has advised KKR on the transaction. Winston & Strawn has advised HealthCare Royalty Partners. KKR has completed the acquisition of a majority ownership...
HealthCare Royalty and Blue Owl Capital Acquire BridgeBio Pharma’s BEYONTTRA Royalty Interest for $300 Million
Gibson Dunn has advised HealthCare Royalty and Blue Owl Capital, and Latham & Watkins has advised BridgeBio Pharma. HealthCare Royalty and Blue Owl Capital have acquired...
HealthCare Royalty’s $250 Million Note Purchase Agreement With OPKO Health
Sidley Austin advised Healthcare Royalty on the deal. HealthCare Royalty, a leading royalty acquisition company, announced its US$250 million non-dilutive note purchase agreement with OPKO Health,...
HealthCare Royalty Partners’ Revenue Financing Agreement with Spero Therapeutics
Cadwalader advised HealthCare Royalty Partners on the deal. HealthCare Royalty Partners closed a revenue financing agreement for up to $125 million for Spero Therapeutics, Inc. (NASDAQ: SPRO),...